Axillary Dissection in Breast Cancer or Just Sentinel Lymph Node Biopsy? A Detailed Analysis

• April 20, 2024
• By Fernando Amato

What are axillary dissection and sentinel lymph node biopsy in breast cancer? When are they indicated and what is their benefit in treatment?

Axillary dissection in breast cancer. A study conducted by J. de Boniface and colleagues shed light on a crucial topic in the surgical approach to breast cancer: the possibility of omitting axillary dissection in selected cases of cancer with metastases in the sentinel lymph node. Therefore, this study, part of a phase 3 clinical trial, focuses on patients with clinically lymph node-negative breast cancer. However, who presented one or two macrometastases in the sentinel lymph node biopsy.

“Revisiting the Need for Complete Axillary Dissection in Breast Cancer Patients”

“Advances in Surgical Treatment of Breast Cancer: The Role of Sentinel Lymph Node Biopsy”

“Axillary Dissection: A Dispensable Step in the Treatment of Certain Breast Cancer Cases?”

1. 🎯 The strategy of omitting complete axillary dissection in selected cases proved to be safe and effective.
2. 📉 The minimally invasive approach resulted in comparable recurrence-free survival to complete axillary dissection.
3. 👥 Previously underrepresented subgroups were included, broadening the applicability of the results.
4. 🚫 Analysis of specific subgroups revealed particular benefits of sentinel lymph node biopsy exclusively in patients with estrogen receptor-positive and HER2-positive disease.
5. 💡 This study contributes to the evolution of surgical practices in breast cancer treatment, promoting more personalized and less invasive approaches.

The Evolution in the Surgical Approach to Breast Cancer

Since the early 2010s, with the results from the American College of Surgeons Oncology Group. Thus, the practice of performing complete axillary dissection after the detection of metastases in one or two sentinel lymph nodes began to be questioned. Therefore, this study demonstrated the safety of omitting this step in patients undergoing breast-conserving surgery and whole-breast radiotherapy. Thus, prompting a significant change in treatment guidelines.

Objectives and Results of the Study by de Boniface et al.

The study led by de Boniface aimed to validate the results of previous trials in a larger and more diverse group of patients. Thus, including those undergoing mastectomy and patients with specific tumor characteristics, such as extracapsular extension in the sentinel lymph node and T3 tumors. The results focused on recurrence-free survival as a pre-specified secondary endpoint.

🔬 Key Findings:

• Five-year recurrence-free survival was similar between the sentinel lymph node biopsy-only groups and those undergoing complete axillary dissection.
• The sentinel lymph node biopsy-only group showed a recurrence-free survival of 89.7%, compared to 88.7% in the dissection group, indicating the non-inferiority of the less invasive approach.

Subgroup Analysis: Focus on Underrepresented Populations

Subgroup analyses revealed that sentinel node biopsy was comparable, if not favorable, to complete axillary dissection in all subgroups. However, except in patients with estrogen receptor-positive and HER2-positive disease, where sentinel node biopsy alone appeared to offer better outcomes. This finding is particularly significant as it highlights the importance of personalizing treatment based on individual tumor characteristics.

Conclusion: Redefining the Treatment Paradigm

In summary, the study by de Boniface et al. provides robust evidence supporting the safe omission of complete axillary dissection in selected breast cancer patients. Thus, marking a step towards less invasive treatments. As the medical community continues to prioritize patients' quality of life. However, along with oncological outcomes, this study serves as a reminder of the importance of adapting treatment approaches to individual patient needs.

Frequently Asked Questions:

1. What is axillary dissection? It is a surgical procedure that removes axillary lymph nodes after the detection of metastases in sentinel lymph nodes. Thus aiming to prevent cancer recurrence.
2. What were the main conclusions of the Work? It demonstrated the safety of omitting axillary dissection in specific patients, without compromising survival outcomes.
3. Which patients were the focus of de Boniface et al.'s study? Patients with clinically lymph node-negative breast cancer and with one or two macrometastases in the sentinel lymph node.
4. What was the main finding of de Boniface et al.'s study? The sentinel lymph node biopsy-only approach was not inferior to complete axillary dissection in terms of recurrence-free survival.
5. Were there differences in outcomes between different patient subgroups? Yes, patients with estrogen receptor-positive and HER2-positive disease particularly benefited from the less invasive approach.
6. Does this study change guidelines for breast cancer treatment? Yes, it provides additional evidence supporting the omission of complete axillary dissection in selected cases, contributing to more personalized and less invasive practices.
7. What are the benefits of omitting complete axillary dissection? Reduced risk of postoperative complications, such as lymphedema, and potentially faster recovery.
8. Can all breast cancer patients omit axillary dissection? No, the decision should be based on specific tumor and patient characteristics, evaluated by a multidisciplinary team.
9. How does this study impact mastectomy patients? It offers a less invasive treatment option without compromising survival outcomes, even for patients undergoing mastectomy.
10. Does this study suggest the sentinel lymph node biopsy approach for all patients? It indicates that, for selected patients, this approach can be safe and effective, but individual evaluation is crucial.

Share this article:

Related articles